Clinical Trials Logo

Head and Neck Neoplasms clinical trials

View clinical trials related to Head and Neck Neoplasms.

Filter by:

NCT ID: NCT01149902 Recruiting - Clinical trials for Head and Neck Cancer

Study of Chemo-Immunotherapy in Head and Neck Cancer Patients

Start date: July 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine safety and feasibility of Chemo-Immunotherapy using cyclophosphamide, docetaxel, OK-432, and autologous immature dendritic cells for patients with relapsed and refractory head and neck squamous cell carcinoma.

NCT ID: NCT01118065 Recruiting - Clinical trials for Head and Neck Cancer

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

Start date: May 2010
Phase: Phase 2
Study type: Interventional

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with progressive or recurrent, unresectable, or metastatic thyroid cancer.

NCT ID: NCT00982436 Recruiting - Clinical trials for Head and Neck Neoplasms

Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer

Start date: September 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of neoadjuvant chemotherapy (chemotherapy given before radiotherapy) using cisplatin and docetaxel, followed by carboplatin given at the same time as radiotherapy in the treatment of locally advanced head and neck cancer.

NCT ID: NCT00970502 Recruiting - Clinical trials for Cancer of the Larynx

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Start date: February 2007
Phase: Phase 1/Phase 2
Study type: Interventional

There is no optimal treatment for patients with recurrent head and neck cancer after previous radiation. Chemotherapy alone is not curative and patients survive an average of only 6 to 10 months. Surgery is not always possible and often cannot remove every cancerous cell. On the other hand, reirradiation with chemotherapy cures approximately 25 to 30% of patients but has significant toxicity with as many as 15 to 20% suffering from life-threatening or fatal complications. Therefore, less toxic and more effective reirradiation regimens are urgently needed. There are extensive data from animal studies and preliminary human studies showing that blocking epidermal growth factor receptor (EGFR) and COX-2 enhances radiation effect and is more effective than either treatment alone. Erlotinib is a FDA approved oral inhibitor of EGFR and celecoxib is a FDA approved COX-2 inhibitor. Both have been well studied in humans and appear to have less severe toxicity than conventional chemotherapeutic agents.

NCT ID: NCT00963326 Recruiting - Clinical trials for Head and Neck Cancer

Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer

Start date: June 2008
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood and tissue samples from patients with larynx cancer, pharynx cancer, or oral cavity cancer.

NCT ID: NCT00901732 Recruiting - Oral Mucositis Clinical Trials

Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer

Start date: May 2009
Phase: Phase 1/Phase 2
Study type: Interventional

Patients who have been diagnosed with a head and/or neck cancer commonly develop oral mucositis (OM). The purpose of this study is to estimate the effect of Caphosol on OM and to evaluate if Caphosol had any effect on clinical outcomes which include quality of life, oral intake, swallowing function and pain.

NCT ID: NCT00900419 Recruiting - Lung Cancer Clinical Trials

Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

Start date: May 3, 2001
Phase:
Study type: Observational

RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.

NCT ID: NCT00898638 Recruiting - Clinical trials for Head and Neck Cancer

Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants

Start date: February 13, 2003
Phase:
Study type: Observational [Patient Registry]

RATIONALE: Collecting and storing samples of tissue, saliva, and blood from patients with cancer and from healthy participants to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing tissue samples from patients with head and neck cancer and from healthy participants.

NCT ID: NCT00855881 Recruiting - Clinical trials for Head and Neck Cancer

Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma

Start date: December 2008
Phase: Phase 2
Study type: Interventional

It is the investigators understanding that the combination of clinical trial with laboratory cellular/molecular assay is relevant to the current promising mainstream, the translational research. The design of this trial fulfills this concept and would be a good example conducting in Mackay Memorial hospital.

NCT ID: NCT00837980 Recruiting - Clinical trials for Head and Neck Cancer

Functional Imaging in HNC Undergoing Chemoradiation

Start date: February 2009
Phase: N/A
Study type: Observational

The purpose of the study is to generate a library of functional imaging and anatomical imaging for patients with head and neck cancers for evaluation of new radiotherapy strategies and planning techniques including IMRT. Secondary aims would be to observe the changes in the cancers as the treatment progresses as well as to define the biologically most active part of the tumor (biological target volume) which could be given more intensive treatment. Tumor volumes seen on different imaging modalities will be compared with a hope of finding an optimal imaging methodology for accurate visualization of the head and neck cancers